Impact of Inhaled Tranexamic Acid in Pulmonary Hemorrhage in Pediatric Intensive Care Unit

Impact of Inhaled Tranexamic Acid in Pulmonary Hemorrhage in Pediatric Intensive Care Unit

This study aimed to detect the impact of inhaled Tranexamic acid® in pulmonary hemorrhage in pediatric intensive care unit.

Pulmonary hemorrhage, often manifested as hemoptysis, can be a severe and life-threatening condition.

Tranexamic acid (TXA)® is a lysine analog that prevents the conversion of plasminogen to plasmin and inhibits plasmin's binding to fibrin, stabilizing the fibrin matrix and reducing bleeding.

Inclusion Criteria:

• Age from 1 to 216 months.
• Both sexes.
• Patients with pulmonary hemorrhage.

Exclusion Criteria:

• Disseminated Intravascular Coagulation (DIC).
• Laryngeal oedema.
• Laryngeal web.
• Contraindications to tranexamic acid include arterial thrombosis, pre-existing coagulopathy, or oral anticoagulant treatment.
• Patients with traumatic lesions such as hemothorax.